Combining Antiangiogenic Agents with Chemotherapy for Advanced Lung Cancer
Author Information
Author(s): Ulahannan Susanna V, Brahmer Julie R
Primary Institution: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital
Hypothesis
Does the addition of antiangiogenic agents improve outcomes in patients with advanced non-small cell lung cancer when combined with chemotherapy?
Conclusion
The study found that adding the antiangiogenic agent bevacizumab to standard chemotherapy improves survival outcomes in patients with advanced non-small cell lung cancer.
Supporting Evidence
- Bevacizumab was shown to improve overall survival compared to chemotherapy alone.
- Patients receiving bevacizumab had a higher response rate and longer time to progression.
- Adverse effects were noted, including increased risk of bleeding and hypertension.
Takeaway
This study shows that giving a special medicine that helps stop blood vessel growth, called bevacizumab, along with regular cancer treatment can help people with a type of lung cancer live longer.
Methodology
The study reviewed clinical data from various trials involving patients with advanced non-small cell lung cancer receiving chemotherapy with or without bevacizumab.
Potential Biases
Potential bias due to the exclusion of patients with squamous cell histology and those with certain health conditions.
Limitations
The study primarily focused on non-squamous NSCLC, limiting generalizability to other types.
Participant Demographics
The study included a diverse group of patients with advanced non-small cell lung cancer, but specific demographic details were not provided.
Statistical Information
P-Value
p = .003
Confidence Interval
95% CI, 0.38-1.16
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website